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Isothermal titration calorimetryα-Lactalbumin (α-LA) can bind oleic acid (OA) to formHAMLET-like complexes,which exhibitedhighly selective
anti-tumor activity in vitro and in vivo. Considering the structural similarity to α-LA, we conjectured that
lactoferrin (LF) could also bind OA to obtain a complex with anti-tumor activity. In this study, LF–OA was
prepared and its activity and structural changes were compared with α-LA–OA. The anti-tumor activity was
evaluated by methylene blue assay, while the apoptosis mechanism was analyzed using ﬂow cytometry and
Western blot. Structural changes of LF–OAwere measured by ﬂuorescence spectroscopy and circular dichroism.
The interactions of OA with LF and α-LA were evaluated by isothermal titration calorimetry (ITC). LF–OA was
obtained by heat-treatment at pH 8.0 with LD50 of 4.88, 4.95 and 4.62 μM for HepG2, HT29, and MCF-7 cells,
respectively, all of which were 10 times higher than those of α-LA–OA. Similar to HAMLET, LF–OA induced
apoptosis in tumor cells through both death receptor- and mitochondrial-mediated pathways. Exposure of
tryptophan residues and the hydrophobic regions as well as the loss of tertiary structure were observed in
LF–OA. Besides these similarities, LF showed different secondary structure changes when compared with α-LA,
with a decrease of α-helix and β-turn and an increase of β-sheet and random coil. ITC results showed that
there was a higher binding number of OA to LF than to α-LA, while both of the proteins interacted with OA
through van derWaals forces and hydrogen bonds. This study provides a theoretical basis for further exploration
of protein–OA complexes.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Recently, a complex of α-LA and oleic acid (OA) was identiﬁed in
humanmilk [1,2], andwas isolated by anion exchange chromatography.
The complex was named as HAMLET (human alpha-lactalbumin made
lethal to tumor cells) and showed highly selective apoptotic activity
against tumor cells both in vivo [3,4] and in clinical trials [5,6].LET, human alpha-lactalbumin
-naphthalenesulfonate; DMEM,
r solution; PI, propidium iodide;
ng 0.05% Tween 20; CD, circular
g constant; n, stoichiometry of
nge; ΔS, entropy change; LD50,
hosphorylated JNK; λmax, the
um; Trp, tryptophan
Nutritional Engineering, China
Road, Haidian, Beijing 100083,
. Open access under CC BY-NC-ND licHAMLET speciﬁcally referred to the complex prepared by the anion-
exchange chromatography column [2,7]; however, this method turned
out to be complicated and had a low yield (less than 10 mg each
time). Therefore, other simplemethods draw the interests of researches
[8–12].
α-LA is structurally conserved among species and HAMLET-like
complexes can be formed in different species [13,14]. Fragments of
bovine α-LA obtained by limited proteolysis can also bind OA and
exhibit anti-tumor activity [15]. Furthermore, an equine lysozyme–OA
complex was formed by heating at 45 °C [16]. The fatty acid-binding
protein, β-lactoglobulin, was also found to form cytotoxic complexes
similar to HAMLET [17]. These results all suggested the possibility that
HAMLET-like complexes could be formed with other proteins.
Lactoferrin (LF) is a globular, iron-binding protein with a molecular
weight of about 80 kDa that is widely represented in various secretory
ﬂuids, such as milk, tears, saliva, seminal plasma and nasal secretions
[18,19]. The structure of the iron-binding region of LF was similar to
that of α-LA [20]. It was reported that the structure of α-LA induced
by release of Ca2+ favors the binding of OA [21,22]. LF as well as α-LA
releases the bound ions at an acidic pH [23] to yield a more openense.
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some similarity to those of α-LA, resulting in the cleavage of intra-
molecular disulﬁde bridges and the exposure of free reactive thiol
groups [24].
Although HAMLET-like complexes have been obtained, the binding
mechanism remains unclear. The study of other possible protein com-
plexes with OA may beneﬁt the exploration of the binding mechanism
of protein and OA. In this study, a LF–OA complex was prepared by a
heat-treatment method. The anti-tumor activity, structural changes
and apoptosis mechanism were analyzed. These results provide a theo-
retical basis for further investigation and clariﬁcation of the binding site
of OA and the development of similar anti-tumor complexes.
2. Materials and methods
2.1. Materials
Bovine LF (85% purity), bovine α-LA (85% purity, Ca2+-free), OA
(C18:1:9 cis, ≥99.0% purity, cell culture tested) and 1-anilino-8-
naphthalenesulfonate (ANS) were obtained from Sigma (Sigma-Aldrich
Chemical Co., St. Louis, MO, USA). Dulbecco's Modiﬁed Eagle's Medium
(DMEM) containing a high level of glucose, RPMI-1640, fetal calf
serum, HEPES buffer solution, penicillin and streptomycin was pur-
chased from Gibco (Life Technologies, USA). All the other chemicals
used were of analytical grade.
2.2. Preparation of protein–OA complexes
LF and α-LA were dissolved in phosphate buffer solution (PBS,
10 mM, pH 8.0) to a ﬁnal concentration of 120 μM. OA was directly
added into the protein solution at 50 molar equivalents (OA:protein).
The mixtures were then incubated at 45 °C in a water bath for 20 min
after vortexing for 30 s. Excess fatty acid in the complexeswas removed
by centrifugation at 4 °C followed by ultraﬁltration using a 3000 kDa
cut-off membrane (Sartorius). The LF solution was treated as above
but without OA acting as the control LF. PBS prepared at the same
volume as the LF solution was subjected to the same procedure and
acted as the control buffer.
2.3. Cell lines and cell cultures
Human hepatoma cells (HepG2), human colon tumor cells (HT29)
and human breast cancer cells (MCF-7) were from the ATCC. All cells
were maintained in media supplemented with 10% fetal bovine
serum, 20 U/ml penicillin, 20 μg/ml streptomycin and 10 mM HEPES
at 37 °C in an atmosphere of 5% CO2. For HepG2 and HT29 cells, the
media was DMEMwhile for MCF-7 cells, it was RPMI-1640.
2.4. Oleic acid measurements
The amount of OA in LF–OA and α-LA–OA was quantiﬁed using the
Free Fatty Acid Quantiﬁcation kit (BioVision, Mountain View, USA)
according to the manufacturer's instructions. Brieﬂy, samples were
added to a 96-well plate at several dilutions and known amounts of OA
samples were prepared as a standard curve. Fatty acid assay buffer was
added to each well to a ﬁnal volume of 50 μL. 2 μL Acyl CoA synthetase
was then added, followed by incubation at 37 °C for 30 min. A solution
of enzymes, enhancer and a fatty acid probe was added to each well.
After 30 min of incubation at 37 °C in the dark, the absorbance was
detected at 570 nm.
2.5. Cell viability assays
Cells were seeded in 96-well plates (Corning, USA) at a density of
1 × 104 cells/well and grown for 24 h. Themediumwas then removed,
and different concentrations of LF–OA, α-LA–OA and OA were addedinto a new medium without FBS. FBS was added into each well at a
ﬁnal concentration of 10% after 30 min. After 24 h of incubation at
37 °C, cell viability was tested by methylene blue assay according to
Felice et al. [26]. The control LF and the control solution were also
added to cells at the same volume.2.6. Apoptosis assay measured by ﬂow cytometry
Cells were seeded into 12-well plates (Corning, USA) at a density of
1 × 105 cells/well and grown for 24 h. LF–OAwas added to thewells at
a ﬁnal concentration of 6 μM, while α-LA–OA was added at a ﬁnal
concentration of 60 μM. After 30 min, FBS was added and the cells were
incubated for another 24 h. For apoptosis assays, cells were analyzed by
ﬂow cytometry using the Annexin V-FITC/propidium iodide (PI) double
staining apoptosis detection kit (eBioscience, Mountain View, CA, USA)
[12]. Cells were gated by dot plots and for each sample, at least
15,000 cells were analyzed using a FACSCalibur instrument equipped
with FACStation running FACSCalibur software (BD Biosciences, San
Diego, CA, USA). Each experiment was performed in triplicate.2.7. Western blot
HepG2 cells were seeded into a 6-well plate (Corning, USA) at a
density of 1 × 106 cells/well and grown for 24 h. LF–OA and the control
LF were added to the wells at a ﬁnal concentration of 6 μM. 100 μMOA
was used as it caused similar apoptosis activity as LF–OA. After 0.5 h,
FBS was added and cells were incubated for another 24 h. Cells treated
with control solution served as the control. Cells were then lysed in
100 μL of RIPA lysis buffer (CST) containing 1 mM PMSF for 10 min on
ice and then centrifuged at 14,000 g for 20 min at 4 °C. The protein
content was measured using a BCA protein assay kit (Pierce, USA). The
lysates containing 20 μg of protein were separated on 10% SDS-PAGE
gels and then electrotransferred onto polyvinylidene diﬂuoride
(PVDF) membranes (Millipore, Temecula, CA, USA) with transfer buffer
(25 mM Tris, 250 mM glycine and 20% methanol) at 200 mA for
120 min. The membranes were blocked in 5% skim milk powder in
PBS buffer containing 0.05% Tween 20 (PBST) for 2 h at room tempera-
ture and immunoblottedwith primary antibody overnight at 4 °C. After
washing with PBST, the membranes were incubated with horseradish
peroxidase-conjugated secondary antibody in PBST containing 5%
skimmilk powder for 1 h at room temperature. After the samewashing
steps, the blots were developed using an ImmobilonWestern Chemilu-
minescent HRP Substrate kit (Millipore) and exposed to X-ray ﬁlm
[27,28].2.8. Fluorescence spectroscopy
The intrinsic ﬂuorescence spectra were measured at room tem-
perature using a RF-5301PC spectroﬂuorometer (Shimadzu, Kyoto,
Japan). The emission spectra were collected between 300 and
500 nmwith an excitation wavelength of 292 nm and a scan interval
of 0.2 nm. The slit widths for excitation and emission were set at
3 nm. All experiments were repeated three times. The protein solu-
tions were diluted with the corresponding buffer to a ﬁnal concen-
tration of 30 μM.
For the ANS-binding measurements, each protein sample was incu-
batedwith 50-fold ANS for 15 min at room temperature in the dark. The
emission spectrum of ANS was recorded between 400 and 600 nm at a
scan interval of 0.2 nm with an excitation wavelength of 390 nm. The
emission ﬂuorescence intensities of ANSwere alsomeasured to exclude
the inﬂuence of unbound ANS. The slit widths of excitation and emis-
sion were set at 3 nm. The protein concentration for all measurements
was 30 μM. All experiments were repeated three times.
Fig. 1. Cell viability after 24 h of treatment with different concentrations of LF–OA and
α-LA–OA as measured by the methylene blue assay. HepG2 (triangle), HT29 (square)
and MCF-7 (diamond) cells were treated by 1, 2, 4, 6 and 8 μM LF–OA complexes
(a); 10, 20, 40, 60 and 80 μM α-LA–OA complexes (b). The data with error bars are
expressed as mean ± s.d. (n = 3).
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Far-UV and near-UV circular dichroism (CD) spectra weremeasured
using a J-810 instrument (Jasco Corporation, Tokyo, Japan) between
200–240 nm and 250–320 nm, respectively. A 1-mm path-length was
used. The scan rate was 50 nm per min with an interval of 0.5 nm and
the response time was set as 8 s. Each spectrum was averaged from
three scans. Baseline spectra were recorded for the buffer and
subtracted from the sample. The protein concentration was 30 μM for
all measurements. The secondary structure was calculated using the
CD Pro software package. All experiments were repeated three times.
2.10. Binding dynamics measured by isothermal titration calorimetry
The binding dynamics of OA to LF and α-LA were carried out at
pH 8.0 (10 mM PBS) and 45 °C using an isothermal titration calorime-
ter (ITC, Nano Series, TA Corporation, USA). LF andα-LA were dissolved
in PBS (10 mM, pH 8.0) to the ﬁnal concentration of 6.41 μM and
11.2 μM, respectively. The titrated OA solution was ﬁrst dissolved in
the alcohol to a concentration of 100 mM and then diluted 100 times
by PBS. 190 μL protein solutions were injected into the sample cell
and an automated sequence of 23 injections, each adding 2 μL OA
solution into the protein solutions spaced at 200 s intervals to allow
complete equilibration, was performed. The stirring rate was set at
150 rpm per min. The data were collected automatically and the
binding constant (K), stoichiometry of binding (n), standard enthalpy
change (ΔH), standard Gibbs free energy change (ΔG) and standard
entropy change (ΔS) were analyzed using Launch NanoAnalyze 2.0
software (TA Corporation).
2.11. Statistical tests
Data are presented as mean values ± SD of three independent
experiments. Statistical analysis was performed using one-way ANOVA
followed by the Student's t test and Duncan's test.
3. Results
3.1. Anti-tumor activity measured by methylene blue assay
The cell viability of tumor cells after treatmentwith LF–OA,α-LA–LA
and OA for 24 h was measured. As shown in Fig. 1a and b, both LF–OA
and α-LA–OA exhibited dose-dependent anti-tumor activity. The half
lethal doses (LD50) for LF–OA were 4.88, 4.95 and 4.62 μM for HepG2,
HT29, and MCF-7 cells, respectively, whereas the LD50 of α-LA–OA
were 50.18, 45.77 and 47.60 μM for HepG2, HT29 and MCF-7 cells. No
anti-tumor activity was observed for the control LF and control buffer
at the same concentrations as the complexes (data not shown).
The anti-tumor activity of OA is shown in Fig. 2, where the LD50
values of OA were 100.31, 92.40 and 96.46 μM for HepG2, HT29 and
MCF-7 cells, respectively. The molecular ratio of OA in LF–OA and
α-LA–LA under the preparation condition was 4 and 1, respectively, as
quantiﬁed by the Free Fatty Acid Quantiﬁcation kit. At the concentration
of the LD50 of LF–OA and α-LA–OA, the actual amount of OA was 19.27
and 47.85 μM(mean value of the three cells), respectively. According to
the cytotoxicity curves of OA in Fig. 2, cell viability at these concentra-
tions was 101% and 84% (mean value), respectively.
3.2. Apoptosis rate induced by LF–OA and LA–OA measured by ﬂow
cytometry
Further conﬁrmation of the anti-tumor activity of LF–OA and α-LA–
OAwas obtained using anAnnexin V-FITC/PI double staining kit (Fig. 3).
At 6 μM, LF–OA induced apoptosis in 34.38% (HepG2, Fig. 3a), 32.75%
(HT29, Fig. 3b) and 35.08% (MCF-7, Fig. 3c) of the total cells. At 60 μM
α-LA–OA, the percentages of apoptotic cells of HepG2 (Fig. 3d), HT29(Fig. 3e) and MCF-7 (Fig. 3f) were 30.45%, 29.81% and 30.96%, respec-
tively. Almost no apoptotic cells were detected when treated with
control LF and control buffer.
3.3. Apoptosis pathways analyzed by Western blot
The expression of apoptosis-related proteins after treatment with
OA, LF–OA and control LF were analyzed by Western blot (Fig. 4). We
ﬁrst measured the expression of cleaved caspase-3, which belongs to
the effector caspase family and directly induces apoptosis. As shown, a
dominant band with an apparent molecular weight of 17 kDa for
cleaved caspase-3 was detected for all treatment groups when com-
pared with control cells.
To examine the pathway of the apoptosis mechanism, proteins
involved in the regulation of mitochondria-mediated and death
receptor-mediated apoptosis pathways were then measured. In the
mitochondria-mediated pathway, Bax, Bcl-2 and caspase-9 are the
primary regulators. As shown in Fig. 4, dominant bands with apparent
molecular weights of 21, 25 and 47 kDa for Bax, Bcl-2 and the intact
caspase-9, respectively, were detected. Cells treated with OA and
LF–OA both showed a higher level of pro-apoptotic Bax accompanied
by a lower level of anti-apoptotic Bcl-2, indicating a higher Bax/Bcl-2
ratio. On the contrary, cells treatedwith control LF showed higher levels
of both Bax and Bcl-2, resulting in a lower Bax/Bcl-2 ratio that was sim-
ilar to control cells. A higher Bax/Bcl-2 ratio leads to the release of
Fig. 2.Cell viability ofHepG2 (a),HT29 (b) andMCF-7 (c) cells after 24 h of treatmentwith
25, 50, 75 and 100 μM OA as measured by the methylene blue assay. The data with error
bars are expressed as mean ± s.d. (n = 3).
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caspase-9 in the cytoplasm. Analysis of the intact caspase-9 suggested
that there was more cleaved caspase-9 in cells treated with OA, LF–OA
and control LF compared with control cells. Akt participates in the
mitochondria-mediated apoptosis pathway and promotes cell survival.
Expression of phosphorylatedAkt (p-Akt)wasdecreased in cells treated
with OA and LF–OAwhile activated in cells treated with control LF. This
result combined with the lower Bax/Bcl-2 ratio favored the idea that no
anti-tumor and apoptosis activity had been observed in cells treated
with control LF.
In the death receptor-mediated apoptosis pathway, caspase-8, the
initial caspase, was activated in cells treatedwith OA, LF–OA and control
LF. Therewere light bands at 57 kDa for intact caspase-8 comparedwith
the control cells (Fig. 4). The death-receptor pathway also activates JNK.
This in turn activates Bax, which is involved in the mitochondria path-
way. Cells treated with OA, LF–OA and control LF all showed increased
expression of phosphorylated JNK (p-JNK) compared with the controlcells. Although LF–OA and control LF shared some similarities in terms
of the expression of proteins that regulate the apoptosis pathways,
when the similar cell viability results for LF–OA and OA were taken
into account, the apoptosis mechanism of LF–OA was more relevant to
that of OA.3.4. Structural characteristics of LF–OA
The exposure of hydrophobic amino acids (Fig. 5a and b) and hydro-
phobic regions (Fig. 5c and d) of LF and α-LA induced by binding of OA
was analyzed by ﬂuorescence spectroscopy. As shown in Fig. 5a, control
LF had an intrinsic ﬂuorescence emission maximum (λmax) at about
332.4 nm while the λmax of LF–OA was signiﬁcantly red-shifted to
337.4 nm. There was also a signiﬁcant red-shift when α-LA binds OA
(Fig. 5b, from 331.2 nm to 337.6 nm). The red-shift of λmax suggested
that tryptophan (Trp) residues were exposed to the solvent. In Fig. 5c,
a remarkable increase in ANS ﬂuorescence intensity together with a
pronounced blue shift of λmax took place when LF binds OA. Similar
changes could also be observed for α-LA–OA, but were less remarkable
(Fig. 5d). These results indicated increasing exposure of hydrophobic re-
gions upon binding of OA.
Far-UV and near-UV CD spectroscopy was used to compare the
secondary and tertiary structures of LF and α-LA induced by binding
of OA (Fig. 6). As shown in Fig. 6A, the near-UV CD spectra of LF–OA
showed lower signal intensities compared with the control LF. α-LA
also exhibited this phenomenon when binding OA (Fig. 6B). The sec-
ondary structure of LF and α-LA with or without OA was calculated
from the far-UV CD spectra according to Yang's reference (Table 1).
LF–OA showed a decrease of α-helix and β-turn structure compared
with the control LF, which turned into β-sheet and random coil
(p b 0.05). Secondary structure changes of α-LA indicated apparent
differences from LF.α-LA had a lower content of β-turn and higher con-
tents ofβ-sheet and random coil accompanied by anunchangedα-helix
content after binding OA. A signiﬁcant increase of random coil was
observed for both α-LA and LF, which indicated the loss of ordered
structure after binding with OA.3.5. Binding dynamics of OA measured by ITC
The binding dynamics of OA to LF and α-LA were monitored by ITC
(Fig. 7). The upper ﬁgures show the raw calorimetric data and in all
cases, the raw ITC data showed exothermic peaks (upward). As the
titration progressed, the exothermic peaks decreased until heat values
of dilution corresponding to the protein in the buffer alone were
reached. The lower ﬁgures show a plot of the total heat generated per
injection as a function of the molar ratio of OA to protein. All binding
isotherms were ﬁt to an independent binding site model and the ther-
modynamic parameters were obtained (Table 2). The heat of dilution
of free OA has been subtracted from this data. The value of K indicates
the binding afﬁnity of the interaction. The Ks of OA to LF and α-LA
were 1.58 × 105 and 2.09 × 105 M−1, respectively, indicating that OA
had almost the same binding strength to both proteins. The values of
n, the number of OA-binding sites, for LF and α-LA under themeasured
condition were 34 and 18, respectively, indicating there were more
binding sites in LF than in α-LA.
Besides the binding kinetics, ITC also measured the thermodynamic
constants during the binding reaction [29–33]. The Gibbs free energy
change, ΔG, which is derived from K, was not signiﬁcantly different
between LF and α-LA. The negative value of ΔG is indicative of sponta-
neous binding of OA to the proteins [34–38]. Furthermore, this exother-
mic binding process is accompanied by negative ΔH and ΔS values
in the cases of both LF and α-LA (Table 2). The negative ΔH and ΔS
changes indicate the importance of van der Waals forces as well as
hydrogen bond formation during the titration of OA [34,35,39].
Fig. 3. Apoptosis induced by LF–OA andα-LA–OA in tumor cells analyzed by ﬂow cytometry using an Annexin V-FITC/PI apoptosis testing kit. HepG2 (a and d), HT29 (b and e) andMCF-7
(c and f) were exposed to 6 μM LF–OA (a–c) or 60 μM α-LA–OA (d–f) for 24 h. Early apoptotic cells only bound to annexin V (the lower right D4 region), necrotic or late apoptotic
cells bound to both annexin V and PI (the upper right D2 region), while viable cells did not bind to either annexin V or PI (the lower left quadrant D3 region). The upper left D1 region
corresponds to cells damaged during the preparation of the cell suspension. The apoptosis rate was calculated after subtracting the value of D1.
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LF as well as α-LA could bind OA to kill tumor cells. The LD50 of
LF–OA was about 10 times lower than that of α-LA–OA, indicating a
much higher anti-tumor activity. OA was found to induce the same
degree and type of cell death as HAMLET at the equivalent dose [40].
Meanwhile, our previous study also found that the anti-tumor activity
of the complexes increased as the amount of OA bound to α-LA
increased [12]. However, according to the results from the Free Fatty
Acid Quantiﬁcation kit, the content of OA in LF–OA was actually lower
than that in α-LA–OA at the LD50 concentration. Therefore, the higher
anti-tumor activity of LF–OA was not because there was a higher con-
centration of OA in the complex, but indicated the protein also played
an important role. α-LA–OA was reported to interact with the tumor
cell membrane, enter into cells and localize at the nucleus. Many studies
have shown that there is high expression of LF receptors on tumor
membranes [41–47], which may favor LF–OA binding to tumor cells
and facilitate subsequent interactions with the membrane. In addition,
fatty acids with an unsaturated C18 alkyl chain, such as OA, wereFig. 4.Expression of cleaved caspase-3, Bax, Bcl-2, intact caspase-9, p-Akt, intact caspase-8 and p
LF for 24 h. Cells treated with only the medium served as the control. The total cell lysate (20reported to be a popular enhancer in the delivery of a variety of drugs
[48]. It can be inferred that the structure of LF–OA was changed when
it interacts with the cell membrane, leading to the exposure of OA,
which destroys the selective permeation function of the cell membrane.
LF–OA induced tumor cell apoptosis (Fig. 4), which was similar to
the anti-tumor mechanism of HAMLET-like complexes [2,7]. Treatment
with LF–OA leads to the outward translocation of phosphatidyl serine,
one of the classic characteristics of apoptosis [49,50]. OA also exhibited
this phenomenon of apoptosis while the control LF did not (data not
shown). Cleaving of caspase-3 can directly lead to apoptosis, which
can be activated through both the intrinsic (mitochondrial) and the
extrinsic (death-receptor) apoptosis pathways [51,52]. Western blot
results suggested that the pro-apoptotic mechanism of LF–OA was
attributed to the presence of OA, which is consistent with the results
from other studies [40,53–58]. Additionally, the control LF also shares
some similarity in its regulation of apoptosis-related proteins with
LF–OA. However, there were also pro-survival pathways, such as the
higher expression of Bcl-2 and activation of Akt to counteract the apo-
ptosis activity. It can be deduced that LF–OA induced apoptosis through-JNK analyzed byWestern blot. HepG2 cellswere treatedwith 100 μMOA, 6 μMLF–OAand
μg) was subjected to immunoblot analysis using speciﬁc antibodies.
Fig. 5. Structural changes induced by binding of OA detected by intrinsic (a, b) and ANS-binding (c, d) ﬂuorescence emission spectra. All spectraweremeasured at room temperature at a
scan interval of 0.2 nm. A and C are spectra of LF samples while B and D are spectra of α-LA samples. Solid lines and dotted lines represent the spectra of control protein and protein–OA
complexes, respectively. The arrow in each ﬁgure indicated the position of λmax.
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tumor activity of protein–OA complexes.
The lipocalins are a family of proteins that can bind small hydropho-
bic molecules such as long chain fatty acids [59]. All members of thisFig. 6. Structural characteristics of LF–OA (a) and α-LA–OA (b) detected by near-UV CD
spectra. All spectra were measured at room temperature at a scan interval of 50 nm/min.
Each spectrum was averaged from three scans. Solid lines and dotted lines represent the
spectra of control protein and protein–OA complexes, respectively.family contain a β-barrel shaped into a ﬂattened calyx, which consti-
tutes the internal binding cavity for small hydrophobic molecules [59].
The binding site for OA in α-LA was reported to be around the Ca2+-
binding cleft [21,22]. LF is composed of two globular lobes of similar
size and 40% sequence identity [60]. Each lobe was folded into
α-helical and β-sheet structures [20,61] and connected by a hinge
region, which created a deep cleft for iron binding [62]. Therefore, it
can be deduced that each lobe of LF could bind OA while there is only
one lobe in α-LA that could bind OA. This was conﬁrmed by the ITC
results. The stoichiometry of OA in LF-OA was almost two-fold that in
LA–OA.
Binding of OA resulted in the exposure of Trp to a more hydrophilic
environment and increased the exposure of hydrophobic regions
(Fig. 5). In addition, LF–OA showed a loss of tertiary structure compared
with the control LF. These spectroscopic features are consistent with
those of α-LA–OA [7–9,15,16,18,63]. The difference between LF–OA
and α-LA–OA is the change of secondary structure content. LF–OA
showed a decrease of α-helix and β-turn while in α-LA–OA the
α-helix was unchanged and the β-turn decreased. However, both
LF–OA and α-LA–OA showed an increase in β-sheet and random coil,
which may explain the loss of tertiary structure.
All chemical, physical, and biological processes are accompanied by
changes in thermodynamic parameters [36,37].ΔGdetermineswhether
a reaction can take place spontaneously under certain conditions, while
changes in ΔH and ΔS reﬂect the interaction forces. ΔH reﬂects
the amount of heat released or absorbed during the course of theTable 1
Secondary structure content calculated from the far-UV CD according to Yang's reference.
Content (%) LF–OA Control LF LA–OA Control α-LA
α-Helix 19.51 ± 0.52 ⁎ 25.13 ± 0.91 26.40 ± 0.25 26.07 ± 0.25
β-Sheet 36.70 ± 2.77 ⁎ 28.50 ± 0.89 20.36 ± 0.72 ⁎ 14.30 ± 0.66
β-Turn 12.45 ± 1.73 ⁎ 15.64 ± 0.35 17.00 ± 0.47 ⁎ 20.26 ± 0.31
Random 31.34 ± 0.46 ⁎ 30.73 ± 0.06 36.27 ± 0.45 ⁎ 39.37 ± 0.26
⁎ Indicates p b 0.05.
Fig. 7. Calorimetric titration (upper ﬁgure) and plots of the integrated heat versus each injection (lower ﬁgure) ﬁt to an independent binding site model. 1.68 mM OA was titrated to
6.41 μM LF (solid lines) or 11.2 μM α-LA (dotted lines) at 45 °C with a stirring rate of 150 rpm/min. Both the proteins and OA were dissolved in 10 mM pH 8.0 PBS.
541B. Fang et al. / Biochimica et Biophysica Acta 1841 (2014) 535–543reaction [36,37,64] while ΔS reﬂects a change in the degree of order of
the system, which is also inﬂuenced by changes in the conformation
of the macromolecules and the restriction of degrees of freedom of the
main chain and side groups of macromolecules [36,37]. The interaction
between endogenous or exogenous ligands and biological macromole-
cules involves not only electrostatic interactions and hydrophobic inter-
actions but also hydrogen bonds and van derWaals interactions [39,65].
Previous studies inferred that α-LA interacts with OA through hydro-
phobic [3,66] or electrostatic [67] interactions. In our study, the negative
value of ΔH and ΔS during the binding reactions indicated that van der
Waals forces and hydrogen bonds play a major role in OA binding to LF
and α-LA [34,39,65,68].
In conclusion, LF can bind OA to form HAMLET-like complexes but
with a much higher anti-tumor activity. LF–OA kills tumor cells by
inducing apoptosis, which was initiated by both the mitochondria-
mediated intrinsic pathway and death receptor-mediated extrinsic
pathway. Besides its anti-tumor mechanism, the structural changes of
LF induced by OA binding were also similar to those observed for the
HAMLET-like complexes, including exposure of Trp residues and the
hydrophobic clusters. Although the change of α-helix and β-turn con-
tent is different between LF and α-LA, both proteins showed increased
content of β-sheet and random coil. LF exhibited a higher afﬁnity to
OA than to α-LA although both proteins interacted with OA through
van der Waals interactions and hydrogen bonds. Although follow-up
studies on the complexes are needed, the study revealed a novel anti-
tumor HAMLET-like complex. This study provides the theoretical basis
for exploration of proteins that acquire new biological activities after
complex formation with small molecules such as fatty acids.Table 2
ITC results.a
OA binding kinetics n K (M−1)
LF 34.77 ± 0.30 (1.58 ± 0.83) × 105
α-LA 18.51 ± 0.10 (2.09 ± 1.39) × 105
a The reported thermodynamic parameters are apparent values and include the contribution
parameters n, K, and ΔH are obtained from the ITC ﬁtting software, Launch NanoAnalyze 2.0.
b Calculated from ΔS = (ΔH − ΔG) / T.
c Calculated from ΔG = −RTlnK.5. Conclusions
Questions have been raised as to whether anti-tumor complexes
similar to HAMLET can be formed from other proteins. This study
revealed that LF could also bind OA and induce apoptosis in tumor
cells. Both LF and α-LA interact with OA through van der Waals forces
and hydrogen bonds. LF–OA induced high anti-tumor activity through
apoptosis initiated by both death-receptor and mitochondrial-
mediated pathways. The binding capability of OA in LF was about
twice that of OA in α-LA. Although it was reported that the anti-tumor
activity of HAMLET depends on OA, our study found that both the pro-
tein and OA were responsible for the anti-tumor activity. Structural
changes of LF induced by bindingOAwere similar to HAMLET, including
the exposure of Trp residues and hydrophobic surface areas, loss of
tertiary structure and increased content of β-sheet and random coil
structures. Our study conﬁrmed the presence of a novel HAMLET-like
complex, while the comparison of LF–OA and α-LA–OA provides new
information on the interactions between the proteins and OA, which
provides a theoretical basis for further investigations.Acknowledgements
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Program.ΔH (kJ/mol) ΔS (kJ/mol)b ΔG (kJ/mol)c
−145.12 ± 10.63 −356.51 ± 21.7 −31.65 ± 1.87
−186.90 ± 12.49 −485.53 ± 30.9 −32.39 ± 2.22
s to the overall equilibrium from fatty acid, protein and buffer species. The thermodynamic
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